enVVeno Medical (NASDAQ: NVNO) releases updated investor presentation

Q: What did enVVeno Medical Corporation (NVNO) disclose on July 14, 2026?

enVVeno Medical Corporation disclosed that it issued an investor presentation on July 14, 2026. The presentation may be used in meetings with investors, analysts and others and is furnished as Exhibit 99.1 under Regulation FD.

Q: How will enVVeno Medical (NVNO) use the new investor presentation?

The company stated that the investor presentation may be used in whole or in part, with possible modifications, in meetings with investors, analysts or others from time to time. It serves as a communication tool to explain the company’s story and information.

Q: Is enVVeno Medical’s (NVNO) investor presentation considered filed with the SEC?

The investor presentation is furnished , not deemed filed, for purposes of Section 18 of the Exchange Act. It is also not incorporated by reference into Securities Act or Exchange Act reports unless expressly referenced in a specific future filing.

Q: Which exhibit contains enVVeno Medical’s (NVNO) latest investor presentation?

The latest investor presentation is included as Exhibit 99.1 . Another exhibit, 104, covers the Cover Page Interactive Data File embedded within the Inline XBRL document, which provides the structured data for the cover page information.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

enVVeno Medical Corporation disclosed that on July 14, 2026 it issued an investor presentation that may be used in meetings with investors, analysts and others. The presentation is provided as Exhibit 99.1 and is furnished under Regulation FD, not deemed filed or incorporated by reference under the Exchange Act except if specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Date of investor presentation: July 14, 2026 Par value per share: $0.00001 per share Commission File Number: 001-38325 +1 more

4 metrics

Date of investor presentation July 14, 2026 Date enVVeno Medical Corporation issued the investor presentation

Par value per share $0.00001 per share Par value of enVVeno Medical Corporation common stock

Commission File Number 001-38325 SEC Commission File Number for enVVeno Medical Corporation

Exhibit number for presentation 99.1 Exhibit number assigned to the investor presentation

Key Terms

Regulation FD, emerging growth company, Inline XBRL, investor presentation

4 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure. On July 14, 2026"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

emerging growth company regulatory

"Emerging growth company Item 7.01 Regulation FD"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

investor presentation financial

"issued an investor presentation, which may be used"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/14/2026 - 04:56 PM Accepted by SEC EDGAR 07/14/2026 - 04:55 PM

FAQ

What did enVVeno Medical Corporation (NVNO) disclose on July 14, 2026?

enVVeno Medical Corporation disclosed that it issued an investor presentation on July 14, 2026. The presentation may be used in meetings with investors, analysts and others and is furnished as Exhibit 99.1 under Regulation FD.

How will enVVeno Medical (NVNO) use the new investor presentation?

The company stated that the investor presentation may be used in whole or in part, with possible modifications, in meetings with investors, analysts or others from time to time. It serves as a communication tool to explain the company’s story and information.

Is enVVeno Medical’s (NVNO) investor presentation considered filed with the SEC?

The investor presentation is furnished, not deemed filed, for purposes of Section 18 of the Exchange Act. It is also not incorporated by reference into Securities Act or Exchange Act reports unless expressly referenced in a specific future filing.

Which exhibit contains enVVeno Medical’s (NVNO) latest investor presentation?

The latest investor presentation is included as Exhibit 99.1. Another exhibit, 104, covers the Cover Page Interactive Data File embedded within the Inline XBRL document, which provides the structured data for the cover page information.

On which exchange is enVVeno Medical (NVNO) common stock listed?

enVVeno Medical Corporation’s common stock, with a par value of $0.00001 per share, is listed on The NASDAQ Stock Market LLC under the trading symbol NVNO, giving investors access to trade its equity on a major U.S. exchange.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2026

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-38325		33-0936180
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

70 Doppler

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

(949) 261-2900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		NVNO		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 14, 2026, enVVeno Medical Corporation (the “Company”) issued an investor presentation, which may be used by the Company, including at meetings with investors, analysts or others, in whole or in part and possibly with modifications, from time to time. A copy of the investor presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Set forth below is a list of Exhibits included as part of this Current Report:

Exhibit No.		Description
99.1		Investor Presentation issued by enVVeno Medical Corporation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.